AMO pull out of B&L bid

Article

Advanced Medical Optics (AMO) has withdrawn its bid to buy Bausch & Lomb (B&L), according to a letter issued to B&L by AMO president, James V. Mazzo. The decision was made after B&L refused to grant more time to AMO to prove that it could gain the support needed from shareholders.

Advanced Medical Optics (AMO) has withdrawn its bid to buy Bausch & Lomb (B&L), according to a letter issued to B&L by AMO president, James V. Mazzo. The decision was made after B&L refused to grant more time to AMO to prove that it could gain the support needed from shareholders.

B&L had been trying to decide between AMO's cash and stock offer and a $65 per share all-cash offer made by the private equity firm Warburg Pincus in May. B&L initially accepted the latter but was allowed to solicit better offers during a 50-day "go shop" period. AMO made its offer on 5th July, the last day of the go-shop period.

On 24th July, B&L told AMO that it preferred Warburg Pincus' offer and gave the company until 3rd August to provide concrete, credible evidence of shareholder approval. AMO responded that it needed several weeks to convince its shareholders of the deal's potential value, however, this extension was not granted by B&L, hence AMO's decision to withdraw.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.